Utility of the HAS‐BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug‐Eluting Stent Placement

Abstract

The study shows that the HAS-BLED score can be of utility in risk stratifying patients in determining who can continue DAPT beyond 12 months. Furthermore, a HAS-BLED score of less than 2 may help guide extended DAPT beyond 12 months at minimal bleeding risk. © 2016 Wiley Periodicals, Inc.